U.S. markets closed

Qiagen N.V. (QGEN)

NYSE - NYSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
42.98+0.30 (+0.70%)
Al cierre: 04:00PM EDT
42.90 -0.08 (-0.19%)
Fuera de horario: 05:16PM EDT

Qiagen N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo5,900

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Thierry BernardCEO, MD & Member of Management Board1.99MN/D1965
Dr. Roland SackersCFO, MD & Member of Management Board1.07MN/D1969
Mr. Antonio SantosSenior VP & Head of Global OperationsN/DN/DN/D
Mr. John GilardiVice President of Corporate Communications & Investor RelationsN/DN/DN/D
Ms. Stephany FosterSenior VP & Head of Human ResourcesN/DN/D1979
Dr. Thomas SchweinsSenior Vice President of Life Science Business AreaN/DN/DN/D
Dr. Thomas TheuringerSenior Director & Head of External CommunicationsN/DN/DN/D
Mr. Jean-Pascal ViolaSenior VP & Head of Molecular Diagnostics Business AreaN/DN/DN/D
Dr. Jonathan G. Sheldon Ph.D.Senior Vice President of Qiagen Digital Insights Business AreaN/DN/D1972
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Gestión corporativa

La calificación ISS Governance QuickScore de Qiagen N.V. a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 1; Junta: 3; Derechos del accionista: 5; Compensación: 3.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.